EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 23 (2016) Parasite, 23 (2016) 17 References
Open Access
Issue
Parasite
Volume 23, 2016
Article Number 17
Number of page(s) 8
DOI https://doi.org/10.1051/parasite/2016017
Published online 07 April 2016
  1. Alarcon JB, Waine GW, McManus DP. 1999. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Advances in Parasitology, 42, 343–410. [CrossRef] [PubMed] [Google Scholar]
  2. Bai Y, He S, Zhao G, Chen L, Shi N, Zhou H, Cong H, Zhao Q, Zhu XQ. 2012. Toxoplasma gondii: bioinformatics analysis, cloning and expression of a novel protein TgIMP1. Experimental Parasitology, 132(4), 458–464. [CrossRef] [PubMed] [Google Scholar]
  3. Carey KL, Jongco AM, Kim K, Ward GE. 2004. The Toxoplasma gondii rhoptry protein ROP4 is secreted into the parasitophorous vacuole and becomes phosphorylated in infected cells. Eukaryotic Cell, 3(5), 1320–1330. [CrossRef] [PubMed] [Google Scholar]
  4. Chen H, Chen G, Zheng H, Guo H. 2003. Induction of immune responses in mice by vaccination with Liposome-entrapped DNA complexes encoding Toxoplasma gondii SAG1 and ROP1 genes. Chinese Medical Journal, 116(10), 1561–1566. [PubMed] [Google Scholar]
  5. Dawson HD, Beshah E, Nishi S, Solano-Aguilar G, Morimoto M, Zhao A, Madden KB, Ledbetter TK, Dubey JP, Shea-Donohue T, Lunney JK, Urban JJ. 2005. Localized multigene expression patterns support an evolving Th1/Th2-like paradigm in response to infections with Toxoplasma gondii and Ascaris suum. Infection and Immunity, 73(2), 1116–1128. [CrossRef] [PubMed] [Google Scholar]
  6. Dziadek B, Gatkowska J, Brzostek A, Dziadek J, Dzitko K, Grzybowski M, Dlugonska H. 2011. Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis. Vaccine, 29(4), 821–830. [CrossRef] [PubMed] [Google Scholar]
  7. El-Kady IM. 2011. T-cell immunity in human chronic toxoplasmosis. Journal of the Egyptian Society of Parasitology, 41(1), 17–28. [PubMed] [Google Scholar]
  8. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever A, Kuhn R, Muller W, Trinchieri G, Sher A. 1996. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. Journal of immunology, 157(2), 798–805. [Google Scholar]
  9. Israelski DM, Remington JS. 1993. Toxoplasmosis in patients with cancer. Clinical Infectious Diseases, 17(Suppl 2), S423–S435. [CrossRef] [Google Scholar]
  10. Kang H, Remington JS, Suzuki Y. 2000. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. Journal of Immunology, 164(5), 2629–2634. [CrossRef] [Google Scholar]
  11. Lu G, Zhou A, Meng M, Wang L, Han Y, Guo J, Zhou H, Cong H, Zhao Q, Zhu XQ, He S. 2014. Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the SAG5D gene of Toxoplasma gondii. BMC Infectious Diseases, 14, 3862. [CrossRef] [PubMed] [Google Scholar]
  12. Lu G, Wang L, Zhou A, Han Y, Guo J, Song P, Zhou H, Cong H, Zhao Q, He S. 2015. Epitope analysis, expression and protection of SAG5A vaccine against Toxoplasma gondii. Acta Tropica, 146, 66–72. [CrossRef] [PubMed] [Google Scholar]
  13. Martin DM, Berriman M, Barton GJ. 2004. GOtcha: a new method for prediction of protein function assessed by the annotation of seven genomes. BMC Bioinformatics, 5, 178. [CrossRef] [PubMed] [Google Scholar]
  14. Meng M, He S, Zhao G, Bai Y, Zhou H, Cong H, Lu G, Zhao Q, Zhu XQ. 2012. Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14–3-3 protein in BALB/c mice. Parasites & Vectors, 5, 273. [CrossRef] [PubMed] [Google Scholar]
  15. Meng M, Zhou A, Lu G, Wang L, Zhao G, Han Y, Zhou H, Cong H, Zhao Q, Zhu XQ, He S. 2013. DNA prime and peptide boost immunization protocol encoding the Toxoplasma gondii GRA4 induces strong protective immunity in BALB/c mice. BMC Infectious Diseases, 13, 494. [CrossRef] [PubMed] [Google Scholar]
  16. Niedelman W, Gold DA, Rosowski EE, Sprokholt JK, Lim D, Farid AA, Melo MB, Spooner E, Yaffe MB, Saeij JP. 2012. The rhoptry proteins ROP18 and ROP5 mediate Toxoplasma gondii evasion of the murine, but not the human, interferon-gamma response. PLoS Pathogens, 8(6), e1002784. [CrossRef] [PubMed] [Google Scholar]
  17. Peixoto L, Chen F, Harb OS, Davis PH, Beiting DP, Brownback CS, Ouloguem D, Roos DS. 2010. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. Cell Host & Microbe, 8(2), 208–218. [CrossRef] [PubMed] [Google Scholar]
  18. Quan JH, Chu JQ, Ismail HA, Zhou W, Jo EK, Cha GH, Lee YH. 2012. Induction of protective immune responses by a multiantigenic DNA vaccine encoding GRA7 and ROP1 of Toxoplasma gondii. Clinical and Vaccine Immunology, 19(5), 666–674. [CrossRef] [Google Scholar]
  19. Romano P, Giugno R, Pulvirenti A. 2011. Tools and collaborative environments for bioinformatics research. Briefings in Bioinformatics, 12(6), 549–561. [CrossRef] [PubMed] [Google Scholar]
  20. Sher A, Denkers EY, Gazzinelli RT. 1995. Induction and regulation of host cell-mediated immunity by Toxoplasma gondii. Ciba Foundation Symposium, 195, 95–104. [PubMed] [Google Scholar]
  21. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science, 240(4851), 516–518. [CrossRef] [PubMed] [Google Scholar]
  22. Tenter AM, Heckeroth AR, Weiss LM. 2000. Toxoplasma gondii: from animals to humans. International Journal for Parasitology, 30(12–13), 1217–1258. [CrossRef] [PubMed] [Google Scholar]
  23. Wang HL, Zhang TE, Yin LT, Pang M, Guan L, Liu HL, Zhang JH, Meng XL, Bai JZ, Zheng GP, Yin GR. 2014. Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice. PloS One, 9(9), e108377. [CrossRef] [PubMed] [Google Scholar]
  24. Xu Y, Zhang NZ, Tan QD, Chen J, Lu J, Xu QM, Zhu XQ. 2014. Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model. BMC Infectious Diseases, 14, 525. [CrossRef] [PubMed] [Google Scholar]
  25. Yuan ZG, Zhang XX, He XH, Petersen E, Zhou DH, He Y, Lin RQ, Li XZ, Chen XL, Shi XR, Zhong XL, Zhang B, Zhu XQ. 2011. Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in mice. Clinical and Vaccine Immunology, 18(1), 119–124. [CrossRef] [Google Scholar]
  26. Yuan ZG, Zhang XX, Lin RQ, Petersen E, He S, Yu M, He XH, Zhou DH, He Y, Li HX, Liao M, Zhu XQ. 2011. Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18. Vaccine, 29(38), 6614–6619. [CrossRef] [PubMed] [Google Scholar]
  27. Zhang M, Zhao L, Song J, Li Y, Zhao Q, He S, Cong H. 2013. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection. vaccine, 31(41), 4536–4540. [Google Scholar]
  28. Zhao G, Zhou A, Lu G, Meng M, Sun M, Bai Y, Han Y, Wang L, Zhou H, Cong H, Zhao Q, Zhu XQ, He S. 2013. Identification and characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine candidate against toxoplasmosis. Parasites & Vectors, 6, 175. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.